EGFR and lung carcinoma: Glutamine blockade with JHU083 induces robust anti‐tumor immune responses in “uninflamed” and poorly immunogenic EGFR‐driven lung cancer, and JHU083 may enable EGFR‐driven lung cancer more amenable to immunoprevention and immunotherapies.